OTC Derivatives Clearing: Perspectives on the Evolving Regulatory Landscape and Considerations for Policymakers

Report Previously Published by Oliver Wyman
June 8, 2012
Global, Asia-Pacific, EMEA, Latin America, North America

Abstract

In 2009, the G20 stated an ambition of moving standardized over-the-counter (OTC) derivatives from a bilaterally cleared to a centrally cleared model by the end of 2012. This kicked off a wave of new regulations in the US, EU and elsewhere, as well as major investments by banks, clearing houses, custodians and data providers. However, over the last few years, the scale and complexity of the G20 ambition has become clear. The number and variety of end-user clients creates a massive challenge for clearing houses and client-clearers. The regulatory landscape is fragmented across multiple jurisdictions. The structure and capitalization of the central clearing house industry itself is proving contentious, and questions have arisen over the potential operational and systemic risks of the large scale move to central clearing.

2012-13 is likely to be a decisive period. The nature and timing of many vital regulations will be clarified, including Dodd-Frank, CPSS-IOSCO, Basel III, and EMIR. These regulations and the responses to them will determine whether central clearing remains a credible and beneficial near-term goal at the scale currently envisaged.

Policymakers’ choices on the detail of regulation will be vital, and these choices are by their nature complex. Oliver Wyman offers four core pieces of advice to policymakers:

Keep safety and simplicity as first principles. In any move of this nature, the risks of unintended consequences are significant. Phased timing and a conservative approach to the change is appropriate. Linked to this, some areas of regulation would benefit from simplification – particularly the initial target product scope, and the extent of the push towards exchange-like market-making and price discovery that is often bundled with clearing regulation.

Ensure adequate incentives for central OTC derivatives clearing. If large parts of the OTC derivatives markets are to be smoothly transferred to central clearing, market participants will need realistic economic incentives in addition to legal requirements. We see a risk today that these incentives will either be insufficient or even negative, potentially resulting in damage to liquidity or a migration to non-standardized products/jurisdictions. This is most notable in the Basel proposals for capitalization of exposures to clearing house default funds, and capital rules for “client-clearer” banks. These proposals in our view strike the wrong balance between “safety” and “adequate incentives” by adding capital to the system but adding it in the wrong place and in the wrong structure.

Seek more transatlantic consistency, and adjust the ambition in smaller G20 markets. Although the FSB is attempting to ensure that G20 members have a level of consistency here, we see three issues to be addressed. First, we still see inconsistencies between EMIR and Dodd Frank that should be addressed. Second, the timing of Basel implementation remains a major transatlantic inconsistency. Third, many G20 members outside the EU and US have yet to decide on how to implement the central clearing mandate (and indeed it is unclear whether central clearing would be of benefit in smaller markets); we see a need for more realism in the G20/FSB ambitions here.

Strengthen clearinghouse risk management requirements. While the CPSSIOSCO requirements for central counterparties are a useful starting point, more is needed to ensure a safe and secure clearinghouse industry. The current requirements risk acting as a “bare minimum” in key areas, and therefore risk creating a race to the bottom in terms of margining/collateral/default fund policies. Particularly in an environment where the major central counterparties (CCP) will be too big to fail – either de facto or de jure – we see a need for stronger global guidelines in these areas.

Celent is a research and advisory firm dedicated to helping financial institutions formulate comprehensive business and technology strategies. Celent publishes reports identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally based analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a member of the Oliver Wyman Group, which is a wholly-owned operating unit of Marsh & McLennan Companies [NYSE: MMC].

Media Contacts

North America
Michele Pace
mpace@celent.com
Tel: +1 212 345 1366

Europe (London)
Chris Williams
cwilliams@celent.com
Tel: +44 (0)782 448 3336

Asia (Tokyo)
Yumi Nagaoka
ynagaoka@celent.com
Tel.: +81 3 3500 3023

Table of Contents

Introduction

3

1. Market Context

4

 

1.1. The Original G20 Ambition and Rationale

4

 

1.2. The Performance of the Central Clearing Model in Past Defaults

5

 

1.3. The OTC Central Clearing Landscape Today

6

2. The Regulatory Landscape Today

8

 

2.1. Profile of the Key Regulations That Will Determine the Shape of Clearing

8

 

2.2. Timing of These Regulations

9

 

2.3. International Differences

10

3. Basel Capital Requirements

11

 

3.1. Profile of the Regulations

11

 

3.2. Analysis of the Incentives or Disincentives to Clear OTC Derivatives Trades Centrally

12

4. Considerations for Policymakers

15

 

4.1. Safety and Simplicity

15

 

4.2. Adequate Incentives

15

 

4.3. Transatlantic Consistency

16

 

4.4. Strengthened CPSS-IOSCO Requirements

16

Sign in to download reports and access personalized information